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Racial/Ethnic Differences in the Risk of Intracranial
Hemorrhage Among Patients With Atrial Fibrillation
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Michael B. Jorgensen, MD, FACC,* Wansu Chen, MS†
Los Angeles and Pasadena, California
Objectives This study was designed to study racial/ethnic differences in the risk for intracranial hemorrhage (ICH) and the
effect of warfarin on ICH risk among patients with atrial fibrillation (AF).
Background Nonwhites are at greater risk for ICH than whites in the general population. Whether this applies to patients with
AF and whether warfarin therapy is associated with comparable risk of ICH in nonwhites are unknown.
Methods We retrospectively identified a multiethnic stroke-free cohort hospitalized with nonrheumatic AF. Warfarin use
and anticoagulation intensity were assessed by searching pharmacy and laboratory records. Crude ICH event
rates were calculated by Poisson regression. Cox proportional hazard models were constructed to assess the
independent effect of race/ethnicity on ICH after adjusting for age, gender, hypertension, diabetes, heart failure,
and warfarin exposure.
Results Between 1995 and 2000, we identified 18,867 qualifying AF hospitalizations (78.5% white, 8% black, 9.5% His-
panic, and 3.9% Asian) and 173 qualifying ICH events over 3.3 years follow-up. Achieved anticoagulation inten-
sity was lower among blacks but not different between the other groups. Warfarin was associated with in-
creased ICH risk in all races, but the magnitude of risk was greater among nonwhites. There were no gender
differences. The hazard ratio for ICH with whites as referent was 4.06 for Asians (95% confidence interval [CI]
2.47 to 6.65), 2.06 for Hispanics (95% CI 1.31 to 3.24), and 2.04 (95% CI 1.25 to 3.35) for blacks.
Conclusions Nonwhites with AF were at greater risk for warfarin-related ICH. Blacks, Hispanics, and Asians were at succes-
sively greater ICH risk than whites. (J Am Coll Cardiol 2007;50:309–15) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.098t
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btrial fibrillation (AF) is highly prevalent, is associated with
5-fold increased risk of stroke (1), and may account for
0% to 15% of all strokes (2). In a pooled analysis of 5
rimary stroke prevention trials, adjusted-dose warfarin
educed all strokes by 68% (4.5% vs. 1.4% per year) (2). This
See page 316
enefit was offset by a significant 0.3% increase in the
nnual risk of major bleeding (placebo 1.0%, warfarin 1.3%),
he most severe of which was intracranial hemorrhage
ICH). The increase in ICH incidence is reported to be
.2% per year (3,4). Go et al. (5) studied more than 11,000
onvalvular AF patients in the Kaiser Permanente Northern
alifornia health plan and reported a 51% reduction in
rom the *Department of Cardiology and the Center for Medical Education, and the
Department of Research and Evaluation, Kaiser Permanente Medical Center
KPMC), Pasadena, California.h
Manuscript received November 7, 2006; revised manuscript received January 8,
007, accepted January 17, 2007.hromboembolic events with warfarin therapy but a dou-
ling of ICH (0.46% vs. 0.23% per year).
Although most subjects in these studies were white, there
re sparse data on whether the risks of anticoagulation among
onwhite patients parallel those of whites. Furthermore, there
re demonstrated racial differences in the background inci-
ence and types of stroke. The stroke incidences of Hispanics
nd blacks are more than twice as high as those of whites (6,7).
hereas ICH (intracerebral or subarachnoid hemorrhage)
ccounts for 15% to 20% of strokes in whites (8), it is
ubstantially higher (20% to 30%) among blacks (9,10), His-
anics (6), and Asians (11,12). Death from ICH is also much
ore common among nonwhites (13).
Because of the higher baseline risk of ICH among
onwhites, it is important to assess whether there are
acial/ethnic differences in AF-related stroke, particularly
CH, and whether nonwhite AF patients are at greater
isk for ICH when treated with warfarin. This study’s
bjective was to evaluate the risk of ICH among white,
lack, Hispanic, and Asian patients with a history of AF
ospitalization.
I
c
f
D
K
fi
D
4
A
b
g
s
(
m
i
p
i
g
m
r
n
R
a
h
w
h
r
A
t
a
n
i
e
h
P
c
(
S
fi
c
a
C
d
d
i
p
m
s
W
o
o
P
m
p
t
o
u
i
a
p
w
F
p
f
d
t
v
w
w
U
t
w
p
d
p
f
s
b
o
T
w
t
u
I
w
I
p
b
310 Shen et al. JACC Vol. 50, No. 4, 2007
Racial Differences in AF-Related ICH July 24, 2007:309–15Methods
Kaiser Permanente Southern Cal-
ifornia (KPSC) is a prepaid health
maintenance organization that has
served at least 2.7 million members,
about 14% of the region’s popula-
tion, for each of the past 10 years.
Membership demographics and so-
cioeconomic and racial/ethnic com-
position are representative of Cali-
fornia. Racial/ethnic information is
administratively assigned on all hos-
pitalized patients. The study proto-
col was approved by our institutional
review board.
nclusion and exclusion criteria. By searching hospital dis-
harge records, we identified all first-time hospitalizations
or AF or atrial flutter between January 1, 1995, and
ecember 31, 2000, among approximately 2.2 million adult
PSC members. Patients were identified by searching the
rst 3 discharge diagnoses for International Classification of
isease, 9th Revision, Clinical Modification (ICD-9) codes
27.31 and 427.32 for AF and atrial flutter, respectively.
ny AF was included, whether permanent or intermittent,
ecause the risk of stroke does not differ between these
roups (14–16). Atrial flutter was included, as the risk for
troke even among “lone atrial flutter” parallels that of AF
17). By referencing ICD-9 and Current Procedural Ter-
inology codes, patients with a history of stroke or transient
schemic attacks, rheumatic heart disease, mitral valvulo-
lasty, mitral valve replacement predating stroke/transient
schemic attack, brain tumor, heart transplantation, and con-
enital heart disease were excluded. Patients with prosthetic
itral valves were excluded because of their particularly high
isk of thromboembolic events and higher target international
ormalized ratio (INR) levels (18).
Other risk factors for stroke listed by the National
egistry of Atrial Fibrillation (19) were identified using
ppropriate ICD-9 codes, including heart failure (HF),
ypertension, and diabetes mellitus (DM). Race/ethnicity
as recorded in our administrative database for 95% of
ospitalized patients. For this study, we grouped patients by
ace/ethnicity into 5 categories: white, black, Hispanic,
sian, or other. The 2.8% of patients identified as belonging
o the “other” group were excluded from analysis.
Follow-up of each patient began on the day of AF
dmission and ended with an outcome event (fatal or
onfatal ICH) or censoring event (non-ICH stroke death,
schemic stroke, mitral valve replacement, carotid endarter-
ctomy within 2 weeks of a stroke, disenrollment from
ealth plan, and the end of study on December 31, 2003).
atients who underwent mitral valve replacement were
ensored, as they may have had a different stroke risk profile
Abbreviations
and Acronyms
AF  atrial fibrillation
CI  confidence interval
DM  diabetes mellitus
HF  heart failure
ICD-9  International
Classification of Disease,
9th Revision, Clinical
Modification
ICH  intracranial
hemorrhage
INR  international
normalized ratio18,20). rtroke event identification. Ischemic strokes were identi-
ed by ICD-9 codes 433–436; ICHs were identified by
odes 430–432. Data sources included hospital records and
computerized matching of Kaiser membership data with
alifornia vital statistics death tapes. Only the primary
iagnosis from hospital files and the underlying cause of
eath from mortality files were used. All computer-
dentified ICHs underwent chart review to confirm that all
atients underwent brain imaging and that ICH was pri-
ary and nontraumatic. Nonqualifying events were cen-
ored at the time of analysis.
arfarin use and anticoagulation intensity. About 92%
f Kaiser members have prescription drug benefits and
btain their drugs through a KPSC-owned pharmacy.
atients are typically dispensed a 100-day supply of
edication, which may last longer because of splitting
ills. All members have laboratory test benefits and
ypically have their prothrombin time tested at a Kaiser-
wned laboratory with an INR target of 2 to 3 for
ncomplicated AF.
We searched our pharmacy and laboratory databases to
dentify warfarin prescriptions and patients’ achieved
nticoagulation intensity. Patients with a filled warfarin
rescription were considered to be continuously taking
arfarin for the 100-day period after receiving the drug.
or between-prescription gaps of 100 days or more,
atients were considered to be continuously taking war-
arin if they had an INR of 2 or greater in the intervening
ays. This was to account for pill-splitting and prescrip-
ions filled at a non-Kaiser pharmacy. A therapeutic INR
alue was considered to be valid for up to 60 days if there
ere no subsequent INR values or if the warfarin supply
as expected to have exhausted and there were no refills.
sing this method, an individual patient may contribute
o the follow-up times of both warfarin-treated and non–
arfarin-treated groups. The proportion of follow-up time that
atients were receiving warfarin according to this schema was
esignated “percent-time receiving warfarin.”
Approximately 60% of patients received 1 warfarin
rescription. We recorded all INR values that were per-
ormed while patients were taking warfarin according to the
chema described. To exclude patients who were prescribed
ut may not have taken warfarin, we included for analysis
nly patients who had3 INR values while taking warfarin.
he INR tests performed during periods when the patients
ere not expected to have been taking warfarin according to
heir supply of warfarin were not included in our anticoag-
lation intensity analyses.
For all patients hospitalized with an ischemic stroke or
CH event, we reviewed their medical records to confirm
hether or not they were taking warfarin, as well as the
NR values at the time of admission. Comparison of
atients’ warfarin use status at the time of stroke defined
y our computerized algorithm and that of our chart
eview showed a 90% consistency rate (kappa  0.78).
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July 24, 2007:309–15 Racial Differences in AF-Related ICHecause warfarin-related stroke rates are associated with
he achieved anticoagulation intensity, we analyzed the
NR values over the follow-up period and at the time of
CH by race/ethnicity. The association between race/
thnicity and INR value at the time of stroke was studied
sing 3 different INR cut points (3.0, 3.5, and 4.0).
tatistical analysis. Continuous variables are reported as
ean  SD or median and interquartile range as appropri-
te. Continuous and categorical variables were compared
mong racial/ethnic groups with the Kruskal-Wallis test or
hi-square test, respectively. Overall and risk factor-
tratified crude event rates were calculated using log-linear
Poisson) regression with a generalized estimating equations
pproach and are reported as per 100 person-years of
ollow-up. Cox proportional hazard models were used to
alculate the effect of race/ethnicity on the risk of stroke
fter adjusting for age, gender, hypertension, DM, HF, and
ercentage time receiving warfarin. Rate ratios and hazard
atios are reported with 95% confidence intervals (CI).
djusted survival curves were constructed from the Cox
odel by setting the covariates at their means. All analyses
ere conducted with SAS software (version 9.1 for Win-
ows, SAS Institute, Cary, North Carolina).
aseline Characteristics of Patients Hospitalized With Atrial Fibrilla
Table 1 Baseline Characteristics of Patients Hospitalized With
Characteristics White Black
n (%) 14,809 (78.5) 1,534 (8.1)
Male, n (%) 8,353 (56.4) 830 (54.1)
Age (yrs)
Mean SD 74 11 68 13
Median (IQR) 75 (67–82) 70 (59–77
Age in yrs, n (%)
55 885 (6.0) 240 (15.7)
55–64 1,814 (12.3) 326 (21.3)
65–74 4,299 (29.0) 445 (29.0)
75–84 5,572 (37.6) 396 (25.8)
85 2,239 (15.1) 127 (8.3)
Stroke risk factors, n (%)
Hypertension 11,348 (76.6) 1,304 (85.0)
Diabetes mellitus 5,103 (34.5) 695 (45.3)
Heart failure 8,489 (57.3) 935 (61.0)
Number of stroke risk factors, n (%)*
4 1,501 (10.1) 139 (9.0)
3 4,682 (31.6) 549 (35.8)
2 4,946 (33.4) 489 (31.9)
1 2,809 (19.0) 276 (18.0)
0 871 (5.9) 81 (5.3)
Follow-up in yrs, median (IQR) 3.2 (1.0–5.1) 3.1 (1.0–5.
Percent time receiving warfarin
0% 6,132 (41.4) 695 (45.3)
1%–40% 2,823 (19.1) 270 (17.6)
41%–80% 2,208 (14.9) 212 (13.8)
81%–100% 3,646 (24.6) 357 (23.3)Risk factors for stroke included age 75 years, hypertension, diabetes mellitus, and heart failure.
IQR  interquartile range.esults
ohort characteristics. In the 6-year period that ended
ecember 2000, we identified 22,196 first-time AF hospi-
alizations, of which 18,867 qualified for analysis (Table 1).
he cohort median age was 74 years; nonwhites were about
years younger than whites. More than half of whites were
lder than 75 years, whereas only about a third of nonwhites
ere. A lesser proportion of Asians and Hispanics were
omen than among whites. Hypertension and HF were
ore prevalent among blacks. Whites were least likely to be
iabetic. Hispanics and Asians had more stroke risk factors
han the other 2 groups. About 40% to 45% of all patients
ere not prescribed warfarin at any time, whereas about
5% of patients took warfarin 80% of follow-up. There
ere no between-group differences.
umber of ICH events and follow-up person-years.
ver the 9-year follow-up period, 185 ICH cases were
dentified. Ten were hemorrhagic conversions of index
schemic strokes, and 2 followed head trauma. By matching
ur AF cohort to California state death records for the
ntire study period, we found no cases of death due to ICH
hat were not captured into our database. There were thus
73 qualifying ICH events that occurred over 63,204
by Race/Ethnicity
l Fibrillation by Race/Ethnicity
Race/Ethnicity
Hispanic Asian All p Value
1,798 (9.5) 726 (3.9) 18,867
1,079 (60.0) 468 (64.5) 10,730 (56.9) 0.0001
67 14 68 12 72 12 0.0001
69 (59–77) 69 (60–76) 74 (66–81) 0.0001
327 (18.2) 114 (15.7) 1,566 (8.3) 0.0001
335 (18.6) 158 (21.8) 2,633 (14.0)
533 (29.6) 232 (32.0) 5,509 (29.2)
440 (24.5) 170 (23.4) 6,578 (34.9)
163 (9.1) 52 (7.2) 2,581 (13.7)
1,385 (77.0) 587 (80.9) 14,624 (77.5) 0.0001
845 (47.0) 332 (45.7) 6,975 (37.0) 0.0001
940 (52.3) 356 (49.0) 10,720 (56.8) 0.0001
159 (8.8) 59 (8.1) 1,858 (9.9) 0.0001
554 (30.8) 212 (29.2) 5,997 (31.8)
560 (31.2) 229 (31.5) 6,224 (33.0)
355 (19.7) 167 (23.0) 3,607 (19.1)
170 (9.5) 59 (8.1) 1,181 (6.3)
3.4 (1.1–5.2) 3.7 (1.5–5.4) 3.3 (1.0–5.1) 0.0001
737 (41.0) 287 (39.5) 7,851 (41.6) 0.067
341 (19.0) 157 (21.6) 3,591 (19.0)
291 (16.2) 98 (13.5) 2,809 (14.9)
429 (23.9) 184 (25.3) 4,616 (24.5)tion
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Racial Differences in AF-Related ICH July 24, 2007:309–15erson-years of follow-up (0.27 ICH events/100 person-
ears). The numbers of ICH (total person-year follow-up)
or each group are as follows: white 112 (49,324), black 19
5,004), Hispanic 23 (6,206), and Asian 19 (2,669).
CH event rate ratios while taking or not taking warfarin. As
hown in Table 2, the crude rate of ICH for the entire
ohort was 0.47 per 100 patient-years while taking warfarin
nd 0.15 while not taking warfarin, a rate ratio of 3.12.
lthough the risk of ICH increased with warfarin therapy
n all groups, there were striking differences in the magni-
ude of increased risk. There was a 15-fold increased risk of
CH among Asians taking warfarin, whereas the rate ratios
or Hispanics and blacks were 4.8 and 5.0, respectively.
arfarin-related ICH risk was lowest among whites at 2.3.
s expected, the magnitude of risk was greater among older
ersons, but there were no gender differences in warfarin-
elated ICH in this cohort. Patients with hypertension had
3.3-fold risk of ICH while taking warfarin. Those with 1
r more risk factors had a 3-fold risk for ICH, whereas there
as only a single ICH event in each group among patients
ithout risk factors. The ICH risk increased with warfarin
hether or not DM or HF was present.
djusted hazard ratios. After adjusting for age, gender,
ypertension, DM, HF, and percent time treated with
arfarin, Hispanics and blacks had twice the risk for ICH as
Intracranial Hemorrhage Event Rates
Table 2 Intracranial Hemorrhage Event Rate
Receivin
ICH events
Total person-yrs 24
Crude event rate/100 person-yrs (95% CI) 0.47
ICH/total person-yrs (rate)
White 66/19,086
Black 14/1,807
Hispanic 17/2,313
Asian 17/971
Age (yrs)
75 49/8,529
75 65/15,650
Gender
Female 45/9,874
Male 69/14,304
Hypertension
Yes 107/21,143
No 7/3,036
Diabetes mellitus
Yes 46/10,321
No 68/13,858
Heart failure
Yes 73/15,347
No 41/8,831
Stroke risk factors*
1 113/23,157
0 1/1,021
*Risk factors for stroke include age 75 years, hypertension, diabete
CI  confidence interval; ICH  intracranial hemorrhage.hites, whereas Asians were at 4 times the risk (Table 3, Aig. 1). There was a 4% increased risk of ICH with each
dvancing year in age. Patients with 41% time receiving
arfarin had a 1.8- to 2.1-fold risk of ICH compared with
hose who were not treated with warfarin. Hypertension,
arin Not Receiving Warfarin Rate Ratio (95% CI)
59
39,025
–0.83) 0.15 (0.12–0.20) 3.12 (2.28–4.27)
) 46/30,238 (0.15) 2.27 (1.56–3.31)
) 5/3,197 (0.16) 4.95 (1.78–13.75)
) 6/3,892 (0.15) 4.77 (1.88–12.09)
) 2/1,698 (0.12) 14.86 (3.43–64.30)
) 38/16,343 (0.23) 2.47 (1.62–3.77)
) 21/22,682 (0.09) 4.49 (2.74–7.34)
) 27/17,092 (0.16) 2.89 (1.79–4.65)
) 32/21,933 (0.15) 3.31 (2.17–5.03)
) 50/32,106 (0.16) 3.25 (2.32–4.55)
) 9/6,919 (0.13) 1.77 (0.66–4.76)
) 23/14,817 (0.16) 2.87 (1.74–4.74)
) 36/24,207 (0.15) 3.30 (2.20–4.94)
) 38/19,288 (0.20) 2.41 (1.63–3.57)
) 21/19,737 (0.11) 4.36 (2.58–7.38)
) 58/36,018 (0.16) 3.03 (2.21–4.16)
) 1/3,006 (0.03) 2.94 (0.18–47.08)
heart failure.
djusted Hazard Ratio for Intracranial Hemorrhage
Table 3 Adjusted Hazard Ratio for Intracranial Hemorrhage
Hazard Ratio 95% CI p Value
Race
White 1 —
Black 2.05 1.25–3.36 0.005
Hispanic 2.06 1.31–3.24 0.002
Asian 4.06 2.48–6.66 0.0001
Gender
Male 1 —
Female 0.86 0.63–1.17 0.33
Age (per yr) 1.04 1.03–1.06 0.0001
Hypertension 1.52 0.90–2.57 0.12
Diabetes 0.90 0.66–1.23 0.50
Heart failure 1.14 0.82–1.57 0.43
Percent time receiving warfarin
0% 1 —
1%–40% 0.63 0.36–1.08 0.095
41%–80% 1.76 1.13–2.73 0.012
80% 2.13 1.46–3.10 0.0001s
g Warf
114
,179
(0.27
(0.34
(0.77
(0.73
(1.75
(0.57
(0.42
(0.46
(0.48
(0.51
(0.23
(0.45
(0.49
(0.48
(0.46
(0.49
(0.10bbreviations as in Table 2.
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July 24, 2007:309–15 Racial Differences in AF-Related ICHM, and HF were not independently associated with ICH
n this cohort.
chieved anticoagulation intensity. The median monthly
umber of INR values ranged from 2.51 in Asians to 2.67 in
ispanics (p  0.05). The median duration of patient time
hat INR was 2 was approximately 70% in the entire cohort
Table 4). The patient time in subtherapeutic range (INR2)
as greater in blacks than in the others. Overall, 54.5% of
atient-time was in the therapeutic range (INR 2 to 3), with
lacks having a lower percentage of patient time in this range.
ispanics and Asians were in the therapeutic range for a
imilar percentage of follow-up time as whites. For approxi-
ately 9% of patient time, the INR values were 3, with no
ifferences seen between groups.
NR at the time of ICH. The INR threshold value above
hich ICH and other major hemorrhagic risk increases
aried between studies (21–23); therefore, INR values at the
ime of ICH hospitalization were analyzed using 3.0, 3.5,
nd 4.0 as cut points (Table 5). There was no statistically
ignificant difference between groups in the proportion of
CH patients with INR 3.0 or 4.0, but minorities were
ore likely than whites to have an INR 3.5 at the time
f ICH.
iscussion
he U.S. populace is becoming increasingly racially diverse.
ne in 4 residents is nonwhite, according to the 2000
Figure 1 Adjusted ICH Event-Free Curve
ICH  intracranial hemorrhage.
ercent Time Receiving Warfarin That INR Values Were >2, 2–3, a
Table 4 Percent Time Receiving Warfarin That INR Values Wer
White Black
INR range, median (IQR)
2 69.7 (50.6, 81.5) 63.2 (41.7, 76.7)
2–3 55.2 (36.3, 67.8) 47.8 (27.0, 62.3)
3 9.1 (3.2, 16.2) 9.9 (2.5, 17.2)NR  international normalized ratio; IQR  interquartile range.ensus. In some states (e.g., California), non-Hispanic
hites constitute but half the population. However, litera-
ure on the epidemiology, prognosis, and treatment of
onwhites with AF are remarkably sparse. The Cardiovas-
ular Health Study, which involved about 5,000 subjects,
uggested that the incidence of AF in blacks was less than
alf that of whites, but only 5% of the total cohort was black
24). Data on nonblack minorities are even scarcer. In the
trial Fibrillation Investigators pooled analysis (2), 90%
ere white. Even in the recent AFFIRM (Atrial Fibrillation
ollow-up Investigation of Sinus Rhythm Management)
tudy (15), which included 4,060 patients, only 11% were
onwhite.
acial differences in ICH. There are important racial/
thnic differences in the incidence and mortality of ICH. In
hites, ICH accounts for 15% to 20% of all strokes (6),
hereas in Chinese (25), Japanese (26), and blacks (9), that
ercentage may be 1.5- to 2.0-fold higher. In the Northern
anhattan Stroke Study (6), with whites as referent, the
ge-adjusted relative risk of ICH was 2 to 3 for both
ispanics and blacks of either gender. Klatsky et al. (12)
ound that Northern California Asians had a 1.6-fold risk of
CH compared with whites. Furthermore, the Centers for
isease Control and Prevention reported a higher ICH
ortality among Asians compared with whites (27). Among
atients who died of stroke in the U.S. between 1995 and
998, ICH accounted for 38% in Asians, 35% in Hispanics,
4% in blacks, and 18% among whites (13). These reports
onsistently indicate a higher baseline risk of ICH among
inorities.
isk factors for ICH. Advanced age, hypertension, and
nticoagulation intensity are associated with a greater risk
or warfarin-related bleeding, especially ICH (21,28). In our
ohort, nonwhites were 6 to 7 years younger than whites, yet
he adjusted hazard ratio for ICH was 2- to 4-fold than that
f whites. There was a slightly higher proportion of hyper-
ensives among Asians and blacks, but this does not appear
ufficient to explain the excessive risk observed.
chieved anticoagulation intensity. In this cohort, INR
alues were therapeutic more than half the time. Anticoag-
lation intensity was subtherapeutic more often among
lacks than the other 3 groups, among which there were no
ifferences. The observed excessive risk of ICH among
onwhites can therefore not be explained by over-
nticoagulation.
3 by Race/Ethnicity
, 2–3, and >3 by Race/Ethnicity
e/Ethnicity
ispanic Asian All p Value
(50.9, 80.1) 69.5 (55.3, 81.1) 69.1 (50.3, 81.1) 0.0001
(36.4, 66.9) 53.7 (39.1, 66.7) 54.5 (35.7, 67.4) 0.0001
(3.1, 16.8) 10.4 (3.9, 17.4) 9.2 (3.1, 16.4) 0.21nd >
e >2
Rac
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Racial Differences in AF-Related ICH July 24, 2007:309–15ossible mechanisms. Polymorphisms of the P450 cyto-
hrome CYP2C9, the enzyme responsible for metaboliz-
ng warfarin, partially determine the dose required. Sev-
ral studies have suggested racial differences in population
requencies of certain polymorphisms (29) that result in a
igher risk of warfarin-related serious bleed (30). However,
ther studies have suggested that CYP2C9 polymorphisms
o not fully account for the population differences in
arfarin dose requirement (29). Variants in the gene for
itamin K epoxide reductase complex 1 (VKORC1), the
arget enzyme of warfarin, also affect patients’ response to
arfarin (31,32). Recent studies (33,34) have found that the
requency of the haplotypes predictive of a low warfarin dose
as significantly higher in the Asian-American population
89%) and lower in the African-American population
10% to 14%) than in the European-American population
37% to 42%). Whether this influenced our observation of
igher ICH risks among nonwhites is not known.
linical implications. Because dosing studies of warfarin
ave involved mostly whites, physicians likely dose warfarin
or patients of all races either empirically or based on
omograms derived from predominantly white patients
35). However, several studies have shown that to achieve
he same INR range, Asians require lower warfarin doses,
hites require intermediate doses, and blacks require higher
oses (36,37). It is unknown whether nonwhites in this
ohort had greater fluctuation in INR levels and whether
his influenced the different rates of ICH observed.
An important consideration is whether all races/
thnicities require the same anticoagulation intensity. You
t al. (38) suggested that a target INR of 1.8 to 2.4 is
ssociated with less thromboembolic and hemorrhagic
vents than INRs of 2 to 3 for Chinese patients. There are
ew studies addressing racial differences in the optimal INR
ange. It is important for future studies to assess whether
nticoagulation intensity should be modified based on race.
tudy limitations. This cohort consists of patients who
ad been hospitalized with AF as one of the primary
iagnoses. One study suggested that as few as 30% of AF
atients are ever hospitalized (39). Our results may not
pply to patients who were never hospitalized. ICD-9 codes
ere used for all disease identification in this study. A recent
tudy (40) showed that ICD-9 coding for AF and other
troke risk factors was 80% sensitive and specific. Al-
hough ICD-9 codes may not capture all morbidities, they
nticoagulation Intensity at the Time of Intracranial Hemorrhage b
Table 5 Anticoagulation Intensity at the Time of Intracranial H
R
White Black
INR values, n (%)
3 24 (22.0) 5 (27.8)
3.5 12 (11.0) 5 (27.8)
4.0 10 (9.2) 3 (16.7)
NR  international normalized ratio.ave excellent negative predictive value (0.98) and moderateositive predictive value for ICH (0.54 to 0.77) (41). This
imitation was addressed by manual confirmation of
ll ICH.
In this study, hypertension was considered a dichotomous
isk factor (present/absent). We could not adjust for the
tage of hypertension or the adequacy of blood pressure
ontrol. Nor could we control for other factors known to
ffect the risk of ICH (e.g., alcohol or illicit drug use) or
rugs that interact with warfarin (e.g., acetaminophen or
erbs), which use may be heterogeneous among racial
roups. Despite our use of both pharmacy and laboratory
alues, we cannot ascertain the day-to-day fluctuation of
nticoagulation intensity and whether this influenced the
ates of ICH. Finally, racial/ethnic classification was admin-
stratively assigned rather than self-reported. Our adminis-
rative database did not differentiate between East and
outh Asians, but regional demographics indicate that East
sians predominate.
onclusions
n this multiethnic cohort of patients hospitalized with AF,
ll races experienced increased risk of ICH while taking
arfarin. However, nonwhite patients, especially Asians,
xperienced substantially higher risk for warfarin-related
CH compared with whites. Furthermore, the adjusted
azard ratio for nonwhites was 2- to 4-fold that of whites.
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